D-Cycloserine for Depression

"The parameters of this trial necessitate that participants are aged between 18 to 65. On the other hand, there are 191 clinical trials for those below 18 years old and 979 studies catering to individuals above the age of 65."

"Data on the safety and efficacy of D-Cycloserine is scant, prompting our team to rate its security at a 1. This rating denotes that this trial is only in Phase 1."

"Affirmative. The clinicaltrial.gov page for this research indicates that it is currently recruiting participants, having been first posted on October 12th 2022 and most recently updated on February 16th 2023. There are 12 patients being sought after across one site of enrollment."

"Affirmative. Per the information posted on clinicaltrials.gov, this medical study is actively accepting participants as of now. It was launched on October 12th 2022 and its parameters were most recently edited February 16th 2023; it aims to enroll a total of 12 patients from one site."

"This clinical trial is enrolling 12 volunteers aged 18 to 65 who have been diagnosed with Major Depressive Disorder as per the DSM-5 criteria. Eligibility requirements include: males and females between 18-65 years of age, mentally able to consent to treatment, an adequate antidepressant medication trial within the current episode that was unsuccessful or not tolerated well; a score ≥18 on the HAMD-17 item; no change in psychotropic medications for four weeks prior to randomization; adherance to the treatment schedule; TASS questionnaire completion (TMS adult safety screening); reference range results from blood work (CBC, electrolytes, B"

"The primary outcome of this clinical trial, assessed over a designated period, will be the correlation between individual differences in D-cycloserine serum concentration and associated results. Secondary outcomes include determining the number of participants that demonstrate 50% or greater improvement in depression (as measured by MADRS), changes in self-reported anxiety levels (as gauged with GAD-7 questionnaire) and alterations to depressive symptomatology (evaluated through QIDS-SR)."